beta-D-Ribofuranose 1,2,3,5-tetraacetate
Based on 1 Customer Validation
Beta-D-Ribofuranose 1,2,3,5-tetraacetate is a biochemical reagent that can be used as a biological material or organic compound for life science related research.
For research use only. We do not sell to patients.
- Purity: 98.0%
- CAS No.: 13035-61-5
- Formula: C13H18O9
- Molecular Weight:318.28
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
-
HY-W039930
Methyl β-D-ribofuranoside
-
HY-77956
Thyminose
-
HY-W018772
D-Ribose(mixture of isomers)
-
HY-W018772R
D-Ribose(mixture of isomers) (Standard)
-
HY-W008351
L-Ribose
-
HY-77956R
Thyminose (Standard)
-
HY-W050049
2-Deoxy-2,2-difluoro-D-erythro-pentonic acid γ-Lactone 3,5-dibenzoate
-
HY-W007928R
1-O-Acetyl-2,3,5-Tri-O-benzoyl-beta-D-Ribofuranose (Standard)
-
HY-W101391
DMT-2'O-Methyl-rU Phosphoramidite
-
HY-113949
Methyl 2,3-O-Isopropylidene-β-D-ribofuranoside
-
HY-45492
DMT-2'Fluoro-DG(IB) Amidite
-
HY-76693
2,3-O-Isopropylidene-D-ribonolactone
Biological Activity
β-D-Ribofuranose 1,2,3,4-tetraacetate is a precursor in the synthesis of nucleotides with antiproliferative activity against cancer cells.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 13035-61-5
-
Appearance Solid
-
Molecular Weight 318.28
-
Formula C13H18O9
-
Color White to off-white
-
SMILES
O=C(OC[C@@H]1[C@@H](OC(C)=O)[C@@H](OC(C)=O)[C@H](OC(C)=O)O1)C
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Solvent & Solubility
DMSO : 50 mg/mL (157.09 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 5 mg/mL (15.71 mM); Clear solution
This protocol yields a clear solution of ≥ 5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (50.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 5 mg/mL (15.71 mM); Clear solution
This protocol yields a clear solution of ≥ 5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (50.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (277 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
[1]. Furukawa Y, et al. A novel method for the synthesis of purine nucleosides using Friedel-Crafts catalysts. Chem Pharm Bull (Tokyo). 1968 Jun;16(6):1076-80. [Content Brief]
[2]. Wicke L, et al. Synthesis and antiproliferative activity of quinolone nucleosides against the human myelogenous leukemia k-562 cell line. Arch Pharm (Weinheim). 2013 Oct;346(10):757-65. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 3.1419 mL | 15.7094 mL | 31.4189 mL | 78.5472 mL |
| 5 mM | 0.6284 mL | 3.1419 mL | 6.2838 mL | 15.7094 mL | |
| 10 mM | 0.3142 mL | 1.5709 mL | 3.1419 mL | 7.8547 mL | |
| 15 mM | 0.2095 mL | 1.0473 mL | 2.0946 mL | 5.2365 mL | |
| 20 mM | 0.1571 mL | 0.7855 mL | 1.5709 mL | 3.9274 mL | |
| 25 mM | 0.1257 mL | 0.6284 mL | 1.2568 mL | 3.1419 mL | |
| 30 mM | 0.1047 mL | 0.5236 mL | 1.0473 mL | 2.6182 mL | |
| 40 mM | 0.0785 mL | 0.3927 mL | 0.7855 mL | 1.9637 mL | |
| 50 mM | 0.0628 mL | 0.3142 mL | 0.6284 mL | 1.5709 mL | |
| 60 mM | 0.0524 mL | 0.2618 mL | 0.5236 mL | 1.3091 mL | |
| 80 mM | 0.0393 mL | 0.1964 mL | 0.3927 mL | 0.9818 mL | |
| 100 mM | 0.0314 mL | 0.1571 mL | 0.3142 mL | 0.7855 mL |
beta-D-Ribofuranose 1,2,3,5-tetraacetate Related Classifications
HY-W018334 Related Classifications
Powered by Bioz